Hericium erinaceus has been studied in human clinical trials for cognitive function, mood, and neurological support. The evidence base is promising but modest: multiple small RCTs exist, but large-scale replication is absent. Below are seven benefits supported by the current research literature.
1. Cognitive Support in Mild Cognitive Impairment
The strongest clinical evidence for Lion’s Mane concerns cognitive function in older adults with mild cognitive impairment (MCI). The landmark double-blind, placebo-controlled RCT by Mori et al. (2009), published in Phytotherapy Research, enrolled 50- to 80-year-old Japanese adults diagnosed with MCI and administered 3,000 mg/day of Hericium erinaceus powder for 16 weeks. Mini-Mental State Examination (MMSE) scores improved significantly in the Lion’s Mane group while declining in the placebo group, with scores returning toward baseline four weeks after discontinuation (PMID: 18844328). A subsequent 2019 study by Saitsu et al. confirmed that oral H. erinaceus intake significantly improved MMSE scores and prevented cognitive deterioration over the study period (PMID: 31413233). These results are consistent across two independent Japanese research groups and provide the most credible evidence base for Lion’s Mane’s use in cognitive aging.
2. Nerve Growth Factor Stimulation
Hericium erinaceus contains hericenones and erinacines, two compound classes that stimulate nerve growth factor (NGF) synthesis in preclinical models: a mechanism confirmed by Mori et al. (2008) in human astrocytoma cells (PMID: 18758067). NGF is essential for the survival, maintenance, and differentiation of cholinergic neurons, which are the neurons most affected in Alzheimer’s disease and age-related cognitive decline. A 2023 study by Martínez-Mármol et al. in Journal of Neurochemistry found that hericerin derivatives activated a pan-neurotrophic pathway in hippocampal neurons via ERK1/2 signaling, enhancing spatial memory in rodent models (PMID: 36660878). The 2023 review by Szućko-Kociuba et al. confirmed neurotrophic and neuroprotective effects of H. erinaceus across multiple study types (PMID: 37958943). While the NGF-stimulation mechanism is well-established in cellular and animal research, direct confirmation of NGF elevation in human plasma following oral supplementation requires further clinical investigation.
3. Support for Early Alzheimer’s Disease Progression
A 49-week pilot randomized, double-blind, placebo-controlled study by Li et al. (2020), published in Frontiers in Aging Neuroscience, examined erinacine A-enriched H. erinaceus mycelium in adults with early Alzheimer’s disease. MMSE scores improved significantly in the intervention group, while the placebo group showed a significant decline over the same period (PMID: 32581767). Cognitive Abilities Screening Instrument (CASI) scores confirmed the same directional difference. The researchers proposed that erinacine A’s documented capacity to reduce amyloid-beta plaque deposition and increase insulin-degrading enzyme expression contributed to the observed protection of cognitive function. Alzheimer’s disease is a serious medical condition; Lion’s Mane cannot be claimed to treat or prevent it. These findings suggest preliminary supportive potential and justify further large-scale clinical investigation.
4. Mood and Anxiety Support
A clinical trial by Nagano et al. (2010) administered Lion’s Mane in cookie form (500 mg powder per serving, daily for 4 weeks) to women and found statistically significant reductions in depression subscale and anxiety subscale scores on the Center for Epidemiological Studies Depression Scale compared to placebo (PMID: 20834180). Vigna et al. (2019) confirmed mood improvements in overweight and obese adults after Lion’s Mane supplementation, with increases in circulating pro-BDNF and BDNF levels proposed as a mechanism (PMID: 31118969). The review by Chong et al. (2019) in International Journal of Molecular Sciences analyzed preclinical and clinical data on Lion’s Mane for depressive disorder and concluded that the evidence supports a neurobiological rationale, primarily involving NGF pathways, BDNF induction, and anti-inflammatory effects (PMID: 31881712). These studies are small, and mood-related benefits should be characterized as emerging rather than established.
5. Sleep Quality Improvement
The Vigna et al. (2019) study in overweight adults also documented improvements in self-reported sleep quality alongside mood benefits following H. erinaceus supplementation (PMID: 31118969). Proposed mechanisms include reduced inflammatory cytokine activity and modulation of BDNF: a neurotrophin involved in sleep regulation. The 2025 systematic review by Menon et al. in Frontiers in Nutrition identified sleep quality improvement as a consistent finding across multiple published studies, noting that H. erinaceus enhanced pro-BDNF and BDNF production and promoted hippocampal neurogenesis, effects associated with improved sleep architecture (PMID: 40959699). Sleep outcomes in Lion’s Mane research are typically secondary endpoints rather than primary outcomes, limiting the strength of conclusions. A dedicated RCT targeting sleep as the primary outcome has not been published.
6. Neuroprotective Properties
Hericium erinaceus demonstrates neuroprotective activity across multiple pathways documented in the 2023 review by Szućko-Kociuba et al. (PMID: 37958943). First, Lion’s Mane reduces oxidative stress in neural tissue by inhibiting reactive oxygen species production and upregulating endogenous antioxidant enzymes including superoxide dismutase and catalase. Second, H. erinaceus compounds downregulate pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and upregulate anti-inflammatory cytokines, reducing neuroinflammation. Third, erinacines have been shown in animal models to reduce amyloid-beta plaque deposition and attenuate endoplasmic reticulum stress-induced neuronal death. Fourth, the ERK1/2 signaling pathway activated by hericerin derivatives supports long-term potentiation mechanisms underlying memory formation (PMID: 36660878). These neuroprotective mechanisms are established in cellular and animal research; translation to human clinical outcomes requires continued investigation.
7. Immune Modulation
Hericium erinaceus polysaccharides and beta-glucans demonstrate immunomodulatory activity by binding pattern recognition receptors on immune cells, including dectin-1 on macrophages and dendritic cells. The Friedman 2015 comprehensive review in Journal of Agricultural and Food Chemistry documented that H. erinaceus beta-glucans stimulate innate immune responses, enhance macrophage phagocytosis, and modulate natural killer (NK) cell activity (PMID: 26244378). These immunomodulatory properties are broadly consistent with the beta-glucan pharmacology established across medicinal mushroom research. Clinical data specifically attributing immunological outcomes to Lion’s Mane supplementation in humans is limited — most evidence originates from in vitro and rodent studies. Individuals with autoimmune conditions should consult a healthcare provider before use, as immune stimulation could theoretically exacerbate autoimmune activity.
References
- Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment. Phytother Res. 2009. PMID: 18844328
- Saitsu Y, Nishide A, Kikushima K, Shimizu K, Ohnuki K. Improvement of cognitive functions by oral intake of Hericium erinaceus. Biomed Res. 2019. PMID: 31413233
- Li IC, Chang HH, Lin CH, et al. Prevention of early Alzheimer’s disease by erinacine A-enriched Hericium erinaceus mycelia. Front Aging Neurosci. 2020. PMID: 32581767
- Nagano M, Shimizu K, Kondo R, et al. Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomed Res. 2010. PMID: 20834180
- Vigna L, et al. Hericium erinaceus improves mood and sleep disorders in patients affected by overweight or obesity. Evid Based Complement Alternat Med. 2019. PMID: 31118969
- Chong PS, Fung ML, Wong KH, Lim LW. Therapeutic potential of Hericium erinaceus for depressive disorder. Int J Mol Sci. 2019. PMID: 31881712
- Mori K, Obara Y, Hirota M, et al. Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells. Biol Pharm Bull. 2008. PMID: 18758067
- Szućko-Kociuba I, et al. Neurotrophic and neuroprotective effects of Hericium erinaceus. Int J Mol Sci. 2023. PMID: 37958943
- Martínez-Mármol R, et al. Hericerin derivatives activate a pan-neurotrophic pathway via ERK1/2 signaling. J Neurochem. 2023. PMID: 36660878
- Friedman M. Chemistry, nutrition, and health-promoting properties of Hericium erinaceus. J Agric Food Chem. 2015. PMID: 26244378
- Menon A, et al. Benefits, side effects, and uses of Hericium erinaceus as a supplement: a systematic review. Front Nutr. 2025. PMID: 40959699